An OpenAI researcher is leaving to build a $2bn AI drug startup that has no name yet
No name. No product. No confirmed funding. And, possibly, a $2bn price tag. That is the shape of the newest bet in AI drug discovery. Miles Wang, a researcher at OpenAI, is leaving to start his own company, TechCrunch reported. He is in talks to raise about $200m at a $2bn valuation, with Lightspeed in […] This story continues at The Next Web
Record details
Published: 15 July 2026
Source: The Next Web AI
Category: News
Topics: Healthcare · Finance, VC & PE · Biotech
Retrieved: 16 July 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
TechCrunch · 15 July 2026
A startup that lets AI hack your own network just tripled to $2bn, days after AI models hacked networks for real.
The Next Web AI · 3 August 2026
Nvidia halved its $250bn promise to OpenAI. Then it showed investors what it owns
The Next Web AI · 15 August 2026
OpenAI is showing Kalshi’s World Cup odds inside ChatGPT, its first prediction market deal
The Next Web AI · 15 July 2026
DrugGen 2: A disease-aware language model for enhancing drug discovery
HuggingFace Daily Papers · 8 July 2026
Socioeconomic Inference in LLM Medical Triage: Same Symptoms, Different ZIP Code
arXiv cs.CY · 28 July 2026
How to cite this record
ethics.ai (15 July 2026), “An OpenAI researcher is leaving to build a $2bn AI drug startup that has no name yet,” evidence record 10766, https://ethics.ai/record/10766 (originally published by The Next Web AI).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.